Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1351-1359

  Von Pawel, Joachim ^a   Von Roemeling, Reinhard ^a   Gatzemeier, Ulrich ^a   Boyer, Michael ^a   Elisson, Lars Ove ^a   Clark, Peter ^a   Talbot, Denis ^a   Augustin, Rey ^a   Butler, Thomas W ^a   Hirsh, Vera ^a   Olver, Ian ^a   Bergman, Bengt ^a   Ayoub, Joseph ^a   Richardson, Gary ^a   Dunlop, David ^a   Arcenas, Anthony ^a   Vescio, Robert ^a   Viallet, Jean ^a   Treat, Joseph ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TIRAPAZAMINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0034104328     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1351     Document Type: Article

References (28)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
2. Perrone F, Rossi A, Ianniello GP, et al: Vinorelbine (VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (PTS): Results of a phase III randomized trial. Proc Am Soc Clin Oncol 17:455a, 1998 (abstr 1752)
3. Fossella FV, Lee JS, Hong WK: Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24:455-462, 1997
4. Sandler A, Nemunaitis J, Dehnam C, et al: Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:454a, 1998 (abstr 1747)
5. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998
6. Gatzemeier U, von Pawel J, Gottfried M. et al: Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:454a, 1998 (abstr 1748)
7. Belani CP, Natale RB, Lee JS, et al: Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:455a, 1998 (abstr 1751)
8. Crino L, Conte P, DeMarinus F, et al: A randomised trial of gemcitabine cisplatin (GP) versus mitomycin, ifosamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC): A multi-center phase III study. Proc Am Soc Clin Oncol 17:455a, 1998 (abstr 1750)
9. Klastersky J, Sculier JP, Lacroix H, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 8:1556-1562, 1990
10. Grau C, Overgaard J: Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13:301-309, 1988
11. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549, 1955
12. Vaupel PW, Hockel M: Oxygenation status of human tumors, in Vaupel PW, Kelleher DK, Gunderoth M (eds): Tumor Oxygenation. Stuttgart, Germany, Gustav Fischer Verlag, 1995, pp 219-232
13. Zeman EM, Brown JM, Lemmon MJ, et al: SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242, 1986
14. Brown JM: SR 4233 (Tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170, 1993
15. Holden SA, Teicher BA, Ara G, et al: Enhancement of alkylating agent activity by SR-4233 in FSaIIC murine fibrosarcoma. J Natl Cancer Inst 84:187-193, 1992
16. Done MJ, Brown JM: Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:4633-4636, 1993
17. Done MJ, Brown JM: Potentiation of the anticancer effect of cisplatin by the hypoxic cytotoxin tirapazamine, in Vaupel PW, Kelleher DK, Gunderoth M (eds): Tumor Oxygenation. Stuttgart, Germany, Gustav Fischer Verlag, 1995, pp 125-135
18. Senan S, Rampling R, Graham MA, et al: Phase I and pharmacokinetic study of tirapazamine (SR4233) administered every three weeks. Clin Cancer Res 3:31-38, 1997
19. Rodriguez GI, Valdivieso M, Von Hoff DD, et al: A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15:382, 1996 (abstr 1144)
20. Treat J, Johnson E, Langer C, et al: Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 16:3524-3527, 1998
21. Miller VA, Ng KK, Grant SC, et al: Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cis-platin in patients with advanced non-small-cell lung cancer. Ann Oncol 8:1269-1271, 1997
22. Treat J, Rodriguez G, Miller V, et al: An integrated phase I/II analysis of Tirazone™ (tirapazamine) + cisplatin: Safety and efficacy in advanced non-small cell lung cancer (NSCLC) patients. Proc Am Soc Clin Oncol 17:472a, 1998 (abstr 1815)
23. Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416, 1998
24. Kennedy KA: Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des 2:181-194, 1987
25. Brown JM, Wang LH: Tirapazamine: Laboratory data relevant to clinical activity. Anticancer Drug Des 13:529-539, 1998
26. Gatineau M, Rixe O, Fizazi K, et al: Phase I study of tirapazamine-cisplatin-vinorelbine in patients with inoperable non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:485a, 1998 (abstr 1865)
27. Ng K, Treat J, O'Dwyer P, et al: A phase I trial of the addition of paclitaxel to tirapazamine (TPZ) and cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:496a, 1998 (abstr 1910)
28. Curran WJ, Movsas B, Hancock S, et al: Phase I trial of oral Tirazone™ (tirapazamine, TPZ) shows good bioavailability and tolerance. Proc Am Soc Clin Oncol 17:208a, 1998 (abstr 802)